Meny
Meny
Register your interest on this website. Contact us if you have any questions that remain unanswered through the registration process.
The cost of participating in our clinical trials depends on the clinical trial and method of administration. One systemic intravenous dose costs 25 000 USD. Inclusion in our Clinical trials starts at $16,500.
Advanced cell therapy production is costly due to strict regulations that ensure quality and safety for patients. A specialised production facility, highly skilled personnel, and expensive equipment and consumables are required.
Register your interest on this website. Contact us if you have any questions that remain unanswered through the registration process.
The cost of participating in our clinical trials depends on the clinical trial and method of administration. One systemic intravenous dose costs 25 000 USD. Inclusion in our Clinical trials starts at $16,500.
Advanced cell therapy production is costly due to strict regulations that ensure quality and safety for patients. A specialised production facility, highly skilled personnel, and expensive equipment and consumables are required.
Mesenchymal stem cells (MSCs) are adult multipotent stem cells with anti-inflammatory, immunomodulatory and regenerative characteristics. They exist in various tissues of the body, such as bone marrow and fat, and are present from birth. (1)
Cellcolabs Clinical utilise cells from Cellcolabs AB. These high-quality cells are sourced from bone marrow donated by healthy individuals aged 18-30. Donors undergo rigorous health checks, and the cells are cultured in Cellcolabs’ advanced facility in Stockholm, following MPA regulations and ethical standards.
Mesenchymal Stem Cells (MSCs) sourced from bone marrow have been extensively researched in scientific studies over several decades. A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment was safe compared to placebo. No serious adverse events were discovered across the included studies (2).
Autologous stem cell treatments use cells derived from the patient’s own body. In practice, this often involves extracting MSCs from fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. However, this also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs Clinical utilises cells from Cellcolabs AB. Cellcolabs’ cells are derived from the bone marrow of healthy donors aged 18-30 years and cultivated in their production facility in Stockholm, Sweden.
There are various advantages to allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than those from older people (3-4).
Our clinical trials are focused on exploring the use of MSCs in prevention of cardiovascular disease, ageing frailty and musculoskeletal injuries and degeneration. All our clinical studies have clear inclusion and exclusion criteria.
Generally, one should not participate in a research study if it comes at the expense of other ongoing or planned treatments. All our clinical studies have clear inclusion and exclusion criteria.
Cellcolabs Clinical provides both systemic and local injections of MSC within clinical trials. Systemic treatments involve a dose of 100 million cells. Local injections, such as for knee osteoarthritis, involve 50 million cells.
Depending on the clinical trial, systemic doses of MSC may be delivered as a slow intravenous infusion over 30 minutes, or as a local injection under ultrasound guidance directly into a joint or ligament.
Based on extensive safety studies, MSCs have not shown association with any severe or long–term side effects. Most individuals feel well after the treatment. However, there is a small risk of experiencing tenderness around the injection site and a mild fever or tiredness in the days following the treatment.
Before treatment administration, you will be examined by the study doctor and may undergo specific tests, depending on the trial. The treatment procedure takes between 30 and 60 minutes. After MSC administration, you will spend an additional 90 minutes at the clinic for observation.
MSCs have anti-inflammatory, regenerative, and immunomodulatory properties, and research has indicated their potential for treating, alleviating, or even preventing various medical conditions. However, the effects of MSC treatment may vary between individuals and participation in a clinical trial does not guarantee any results. The purpose of a clinical trial is for researchers to learn more about the possible effects of an intervention or treatment.
There have been no reported cases of tumour formation resulting from MSC treatment in clinical trials.
Yes, all clinical trials are approved by local authorities and national ethics committees.
These countries have a well-established medical infrastructure with high regulatory standards, albeit with a different regulatory approach than organisations like the EMA and FDA. This unique approach allows us as a smaller company to progress faster in our research and development. Additionally, an important factor for us is that the Bahamas has a strong commitment to establishing themselves as leaders in advanced cell therapies.
Warnings focus on unregulated cell-based treatments in the EU and US, where some therapies have not undergone approval or testing. These treatments may be expensive and without guarantees of quality, prompting the FDA to caution against these practices. In contrast, Cellcolabs Clinical exclusively uses Mesenchymal Stem Cells (MSCs) that have received approval from the Swedish Medical Products Agency (MPA) and adhere to Good Manufacturing Practice (GMP) standards.
Mesenchymal stem cells (MSCs) are stromal cells with anti-inflammatory, immunomodulatory and regenerative characteristics. They exist in various tissues of the body, such as bone marrow and fat, and are present from birth. (1)
They regulate the immune system through paracrine signalling, rather than by differentiating into various tissues, as hematopoietic and other multipotent stem cells do.
MSCs function through cell to cell contact and the release of bioactive molecules, such as growth factors, cytokines, and exosomes, stimulating the body’s natural healing processes.
When injected into the body, MSCs interact with the immune system by being engulfed by immune cells such as macrophages. This triggers effects that suppress inflammation and promote tissue regeneration.
Cellcolabs Clinical utilise cells from Cellcolabs AB. These high-quality cells are sourced from bone marrow donated by healthy individuals aged 18-30.
Donors undergo rigorous health checks, and the cells are cultured in Cellcolabs’ advanced facility in Stockholm, following MPA regulations and ethical standards.
Mesenchymal Stem Cells (MSCs) sourced from bone marrow have been extensively researched in scientific studies over several decades.
A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment was safe compared to placebo. No serious adverse events were discovered across the included studies (2).
Register your interest on this website. Contact us if you have any questions that remain unanswered through the registration process.
The cost of participating in our clinical trials depends on the clinical trial and method of administration. One systemic intravenous dose costs 25 000 USD. Inclusion in our Clinical trials starts at $16,500.
Advanced cell therapy production is costly due to strict regulations that ensure quality and safety for patients. A specialised production facility, highly skilled personnel, and expensive equipment and consumables are required.
Mesenchymal stem cells (MSCs) are adult multipotent stem cells with anti-inflammatory, immunomodulatory and regenerative characteristics. They exist in various tissues of the body, such as bone marrow and fat, and are present from birth. (1)
Cellcolabs Clinical utilise cells from Cellcolabs AB. These high-quality cells are sourced from bone marrow donated by healthy individuals aged 18-30. Donors undergo rigorous health checks, and the cells are cultured in Cellcolabs’ advanced facility in Stockholm, following MPA regulations and ethical standards.
Mesenchymal Stem Cells (MSCs) sourced from bone marrow have been extensively researched in scientific studies over several decades. A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment was safe compared to placebo. No serious adverse events were discovered across the included studies (2).
Autologous stem cell treatments use cells derived from the patient’s own body. In practice, this often involves extracting MSCs from fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. However, this also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs Clinical utilises cells from Cellcolabs AB. Cellcolabs’ cells are derived from the bone marrow of healthy donors aged 18-30 years and cultivated in their production facility in Stockholm, Sweden.
There are various advantages to allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than those from older people (3-4).
Our clinical trials are focused on exploring the use of MSCs in prevention of cardiovascular disease, ageing frailty and musculoskeletal injuries and degeneration. All our clinical studies have clear inclusion and exclusion criteria.
Generally, one should not participate in a research study if it comes at the expense of other ongoing or planned treatments. All our clinical studies have clear inclusion and exclusion criteria.
Cellcolabs Clinical provides both systemic and local injections of MSC within clinical trials. Systemic treatments involve a dose of 100 million cells. Local injections, such as for knee osteoarthritis, involve 50 million cells.
Depending on the clinical trial, systemic doses of MSC may be delivered as a slow intravenous infusion over 30 minutes, or as a local injection under ultrasound guidance directly into a joint or ligament.
Based on extensive safety studies, MSCs have not shown association with any severe or long–term side effects. Most individuals feel well after the treatment. However, there is a small risk of experiencing tenderness around the injection site and a mild fever or tiredness in the days following the treatment.
Before treatment administration, you will be examined by the study doctor and may undergo specific tests, depending on the trial. The treatment procedure takes between 30 and 60 minutes. After MSC administration, you will spend an additional 90 minutes at the clinic for observation.
MSCs have anti-inflammatory, regenerative, and immunomodulatory properties, and research has indicated their potential for treating, alleviating, or even preventing various medical conditions. However, the effects of MSC treatment may vary between individuals and participation in a clinical trial does not guarantee any results. The purpose of a clinical trial is for researchers to learn more about the possible effects of an intervention or treatment.
There have been no reported cases of tumour formation resulting from MSC treatment in clinical trials.
Yes, all clinical trials are approved by local authorities and national ethics committees.
These countries have a well-established medical infrastructure with high regulatory standards, albeit with a different regulatory approach than organisations like the EMA and FDA. This unique approach allows us as a smaller company to progress faster in our research and development. Additionally, an important factor for us is that the Bahamas has a strong commitment to establishing themselves as leaders in advanced cell therapies.
Warnings focus on unregulated cell-based treatments in the EU and US, where some therapies have not undergone approval or testing. These treatments may be expensive and without guarantees of quality, prompting the FDA to caution against these practices. In contrast, Cellcolabs Clinical exclusively uses Mesenchymal Stem Cells (MSCs) that have received approval from the Swedish Medical Products Agency (MPA) and adhere to Good Manufacturing Practice (GMP) standards.
Autologous stem cell treatments use cells derived from the patient’s own body. In practice, this often involves extracting MSCs from fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. However, this also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs Clinical utilises cells from Cellcolabs AB. Cellcolabs’ cells are derived from the bone marrow of healthy donors aged 18-30 years and cultivated in their production facility in Stockholm, Sweden.
There are various advantages to allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than those from older people (3-4).
Our clinical trials are focused on exploring the use of MSCs in prevention of cardiovascular disease, ageing frailty and musculoskeletal injuries and degeneration. All our clinical studies have clear inclusion and exclusion criteria.
Generally, one should not participate in a research study if it comes at the expense of other ongoing or planned treatments. All our clinical studies have clear inclusion and exclusion criteria.
Cellcolabs Clinical provides both systemic and local injections of MSC within clinical trials. Systemic treatments involve a dose of 100 million cells. Local injections, such as for knee osteoarthritis, involve 50 million cells.
Depending on the clinical trial, systemic doses of MSC may be delivered as a slow intravenous infusion over 30 minutes, or as a local injection under ultrasound guidance directly into a joint or ligament.
Based on extensive safety studies, MSCs have not shown association with any severe or long–term side effects. Most individuals feel well after the treatment. However, there is a small risk of experiencing tenderness around the injection site and a mild fever or tiredness in the days following the treatment.
Before treatment administration, you will be examined by the study doctor and may undergo specific tests, depending on the trial. The treatment procedure takes between 30 and 60 minutes. After MSC administration, you will spend an additional 90 minutes at the clinic for observation.
MSCs have anti-inflammatory, regenerative, and immunomodulatory properties, and research has indicated their potential for treating, alleviating, or even preventing various medical conditions. However, the effects of MSC treatment may vary between individuals and participation in a clinical trial does not guarantee any results. The purpose of a clinical trial is for researchers to learn more about the possible effects of an intervention or treatment.
There have been no reported cases of tumour formation resulting from MSC treatment in clinical trials.
Yes, all clinical trials are approved by local authorities and national ethics committees.
These countries have a well-established medical infrastructure with high regulatory standards, albeit with a different regulatory approach than organisations like the EMA and FDA. This unique approach allows us as a smaller company to progress faster in our research and development. Additionally, an important factor for us is that the Bahamas has a strong commitment to establishing themselves as leaders in advanced cell therapies.
Warnings focus on unregulated cell-based treatments in the EU and US, where some therapies have not undergone approval or testing. These treatments may be expensive and without guarantees of quality, prompting the FDA to caution against these practices. In contrast, Cellcolabs Clinical exclusively uses Mesenchymal Stem Cells (MSCs) that have received approval from the Swedish Medical Products Agency (MPA) and adhere to Good Manufacturing Practice (GMP) standards.
Register your interest on this website. Contact us if you have any questions that remain unanswered through the registration process.
The cost of participating in our clinical trials depends on the clinical trial and method of administration. One systemic intravenous dose costs 25 000 USD. Inclusion in our Clinical trials starts at $16,500.
Advanced cell therapy production is costly due to strict regulations that ensure quality and safety for patients. A specialised production facility, highly skilled personnel, and expensive equipment and consumables are required.
Mesenchymal stem cells (MSCs) are adult multipotent stem cells with anti-inflammatory, immunomodulatory and regenerative characteristics. They exist in various tissues of the body, such as bone marrow and fat, and are present from birth. (1)
Cellcolabs Clinical utilise cells from Cellcolabs AB. These high-quality cells are sourced from bone marrow donated by healthy individuals aged 18-30. Donors undergo rigorous health checks, and the cells are cultured in Cellcolabs’ advanced facility in Stockholm, following MPA regulations and ethical standards.
Mesenchymal Stem Cells (MSCs) sourced from bone marrow have been extensively researched in scientific studies over several decades. A meta-analysis published in 2021 reviewed 62 randomised clinical trials and concluded that MSC treatment was safe compared to placebo. No serious adverse events were discovered across the included studies (2).
Autologous stem cell treatments use cells derived from the patient’s own body. In practice, this often involves extracting MSCs from fat tissue and injecting the patient with a concentrate including stem cells from the fat. This treatment option is widespread today since it is not classified as a medicinal product. However, this also means that there is no control from medical authorities such as EMA and FDA.
Allogeneic stem cell treatments use the cells obtained from a donor. Cellcolabs Clinical utilises cells from Cellcolabs AB. Cellcolabs’ cells are derived from the bone marrow of healthy donors aged 18-30 years and cultivated in their production facility in Stockholm, Sweden.
There are various advantages to allogeneic MSC treatments produced by companies that follow the EU or US regulations. The quality is strictly regulated and controlled, meaning that we can be certain that the patient receives the intended amount and potency of cells. There is data indicating that MSCs from younger people are more potent than those from older people (3-4).
Our clinical trials are focused on exploring the use of MSCs in prevention of cardiovascular disease, ageing frailty and musculoskeletal injuries and degeneration. All our clinical studies have clear inclusion and exclusion criteria.
Generally, one should not participate in a research study if it comes at the expense of other ongoing or planned treatments. All our clinical studies have clear inclusion and exclusion criteria.
Cellcolabs Clinical provides both systemic and local injections of MSC within clinical trials. Systemic treatments involve a dose of 100 million cells. Local injections, such as for knee osteoarthritis, involve 50 million cells.
Depending on the clinical trial, systemic doses of MSC may be delivered as a slow intravenous infusion over 30 minutes, or as a local injection under ultrasound guidance directly into a joint or ligament.
Based on extensive safety studies, MSCs have not shown association with any severe or long–term side effects. Most individuals feel well after the treatment. However, there is a small risk of experiencing tenderness around the injection site and a mild fever or tiredness in the days following the treatment.
Before treatment administration, you will be examined by the study doctor and may undergo specific tests, depending on the trial. The treatment procedure takes between 30 and 60 minutes. After MSC administration, you will spend an additional 90 minutes at the clinic for observation.
MSCs have anti-inflammatory, regenerative, and immunomodulatory properties, and research has indicated their potential for treating, alleviating, or even preventing various medical conditions. However, the effects of MSC treatment may vary between individuals and participation in a clinical trial does not guarantee any results. The purpose of a clinical trial is for researchers to learn more about the possible effects of an intervention or treatment.
There have been no reported cases of tumour formation resulting from MSC treatment in clinical trials.
Yes, all clinical trials are approved by local authorities and national ethics committees.
These countries have a well-established medical infrastructure with high regulatory standards, albeit with a different regulatory approach than organisations like the EMA and FDA. This unique approach allows us as a smaller company to progress faster in our research and development. Additionally, an important factor for us is that the Bahamas has a strong commitment to establishing themselves as leaders in advanced cell therapies.
Warnings focus on unregulated cell-based treatments in the EU and US, where some therapies have not undergone approval or testing. These treatments may be expensive and without guarantees of quality, prompting the FDA to caution against these practices. In contrast, Cellcolabs Clinical exclusively uses Mesenchymal Stem Cells (MSCs) that have received approval from the Swedish Medical Products Agency (MPA) and adhere to Good Manufacturing Practice (GMP) standards.
1. Krampera M, Le Blanc K. Mesenchymal stromal cells: Putative microenvironmental modulators become cell therapy. Cell Stem Cell. 2021 Oct 7;28(10):1708-1725. doi: 10.1016/j.stem.2021.09.006. PMID: 34624232.
2. Wang Y, Yi H, Song Y. The safety of MSC therapy over the past 15 years: a meta-analysis. Stem Cell Res Ther. 2021;12(1):545. Published 2021 Oct 18. doi:10.1186/s13287-021-02609-x
3. Choudhery MS, Badowski M, Muise A, Pierce J, Harris DT. Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation. J Transl Med. 2014;12:8. Published 2014 Jan 7. doi:10.1186/1479-5876-12-8
4. Oliva, A.A.; McClain-Moss, L.; Pena, A.; Drouillard, A.; Hare, J.M. Allogeneic mesenchymal stem cell therapy: A regenerative medicine approach to geroscience. Aging Med. 2019, 2, 142–146.